OPN-6602 in MM granted FDA Fast Track Designation
The US Food and Drug Administration (FDA) has granted Fast Track Designation to OPN-6602, an oral small-molecule EP300/CBP inhibitor, for patients with relapsed
Multiple Myeloma
Acute Lymphoblastic Leukemia
Multiple Myeloma
SOHO President Dr. John F. DiPersio honored with top AACR award
The award recognizes an individual's achievements and contributions in any aspect of blood cancer research.
SOHO 2026
Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndromes
News
Society Updates
SOHO announces exclusive MDS, AML session on September 8 in Houston; register now
SOHO will hold an exclusive session titled, “Practical Strategies for Optimizing Outcomes in MDS and AML,” starting at 3 pm on Tuesday, September
SOHO 2025
Ambassador Program
Lymphoma
Aggressive B-Cell Lymphomas
Multiple Myeloma
News
Dr. Raheel Iftikhar weighs in on AI in blood cancers
Dr. Iftikhar is the SOHO Ambassador to Pakistan and a consultant clinical hematologist and hematopoietic stem cell transplantation physician at Armed Forces Bone
Lymphoma
Indolent B-Cell Lymphomas
Atezolizumab plus obinutuzumab, radiotherapy combination safe, effective against FL
The researchers added that early indications from their translational substudies suggest that PET radiomics and immune gene analyses provide promise as biomarkers for
SOHO 2026
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
News
Society Updates
Don’t miss SOHO 2026 poster walks
Don’t miss the SOHO 2026 poster walks taking place from Wednesday to Friday during the SOHO 2026 Annual Meeting. More information at soho.click/2026.
Trending now
Leukemia
Chronic Lymphocytic Leukemia
Multiple Myeloma
Researchers find concomitant MM and CLL are clonally unrelated
When multiple myeloma and chronic lymphocytic leukemia appear in the same patient, they do not derive from the same B-cell but rather develop
Lymphoma
Aggressive B-Cell Lymphomas
FDA approves nivolumab in combination with AVD in cHL
The US Food and Drug Administration has approved the checkpoint inhibitor nivolumab (Opdivo) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adult
2026 Tandem Meetings
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
Meetings / Conferences
News
Interim phase 2 analysis shows zamto-cel activity in DLBCL
The chimeric antigen receptor T-cell therapy zamtocabtagene autoleucel (zamto-cel) showed encouraging activity and a favorable safety profile in patients with relapsed or refractory
ASH 2025
Leukemia
Dr. Lane discusses results of triplet combo in BPCDN
Andrew Lane, MD, PhD, of Dana Farber Cancer Institute, reports the results from a phase 2 trial in tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet